COMPASS Pathways Announces Outcome Of 25Mg COMP360 Psilocybin Therapy As Adjunct To SSRI Antidepressants In Open-label Treatment-resistant Depression Study - Benzinga

Submitted by Anonymous (not verified) on Mon, 12/13/2021 - 12:10

COMPASS Pathways Announces Outcome Of 25Mg COMP360 Psilocybin Therapy As Adjunct To SSRI Antidepressants In Open-label Treatment-resistant Depression Study Benzinga

Log in to post comments